Dr Ingrid Heinze-Krauss is to retire as Chief Technology Officer after 15 years with Basilea and will be succeeded by Dr Günter Ditzinger, currently Head of Pharmaceutics. The changes will be effective from 1 February 2016.
Dr Ditzinger joined Basilea in 2002 as CMC Project Leader & Pharmaceutical Development Manager. He was promoted in 2009 to Head of Pharmaceutics, in which position he led the pharmaceutical development and manufacturing group and acted as Dr. Heinze-Krauss's deputy. Prior to joining Basilea, he held various positions with increasing responsibility at Hoechst Marion Roussel in Frankfurt, Germany and at Novartis Pharma in Basel, Switzerland.
Dr Heinze-Krauss joined Basilea at its founding in 2000. She established Basilea's Technical Operations department and has managed the group since 2004.
